Karyopharm Therapeutics (KPTI) Misses Q4 EPS by 571c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($5.71). Revenue for the quarter came in at $34.08 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Pacific Booker Minerals Inc. Adopts Advance Notice Policy for Director Elections
• U.S. presses Meta to agree to A.I. reviews as security concerns rise - NYT